Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

Publisher： Karger

E-ISSN： 1660-2110|108|4|c291-c297

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.108, Iss.4, 2008-04, pp. : c291-c297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

By Jinnouchi Y.   Yamagishi S.   Takeuchi M.   Ishida S.   Jinnouchi Y.   Jinnouchi J.   Imaizumi T.  

Clinical and Experimental Medicine, Vol. 6, Iss. 4, 2006-12 ,pp. : 191-193

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice

By                

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 107-113

Spandidos Publications

Access to resources Recommend Favorite

Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 6, 2015-06 ,pp. : 847-854

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

By Persson Frederik   Rossing Peter   Hovind Peter   Stehouwer Coen   Schalkwijk Casper   Tarnow Lise   Parving Hans-Henrik  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 68, Iss. 8, 2008-01 ,pp. : 731-738

Informa Healthcare

Access to resources Recommend Favorite

Effects of Angiotensin II Type 1 Receptor Blocker on Blood Pressure Variability and Cardiovascular Remodeling in Hypertensive Patients on Chronic Peritoneal Dialysis

By  

Nephron Clin Pract, Vol. 112, Iss. 1, 2009-04 ,pp. : c31-c40

Karger

Access to resources Recommend Favorite